Relation Therapeutics has raised an additional $26 million from existing investors NVentures, DCVC, and Magnetic Ventures as it continues building an AI-driven drug discovery and development platform focused on improving confidence in the underlying biology of disease.
The London-based company said the new capital will support its approach of combining computation, experimentation, and patient data to reduce failure rates in drug development and help advance programs aimed at common diseases.
Relation’s Lab in the Loop platform integrates AI with patient-derived multi-omic data and proprietary experimental systems to identify causal genes and refine target hypotheses. The company said it develops medicines to clinical value inflection points across multiple therapy areas, with a portfolio spanning immunology, metabolic disease, and bone disease.
KEY QUOTES:
“Relation’s unique combination of computation, experimentation, and patient data will reduce failure rates in drug development and transform the way we treat common, devastating diseases. DCVC has supported Relation since its very beginning, and we’re pleased by this further validation of the company’s approach,”
Jason Pontin, General Partner at DCVC
“The mission of Relation is clear – to discover the next generation of medicines through technology, transforming patients’ lives. The continued support of our investors strengthens the base from which we will deliver on this mission.”
David Roblin, CEO of Relation
